Trials / Completed
CompletedNCT00091637
Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)
APEX-AMI - Pexelizumab in Conjunction With Angioplasty
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 5,745 (actual)
- Sponsor
- Procter and Gamble · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention (PCI), the body's own inflammatory system involving the complement cascade may be harmful. This study will test the safety and efficacy of a novel complement inhibitor, pexelizumab to reduce mortality at 30 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pexelizumab | Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once |
| DRUG | Placebo infusion | bolus infusion over a 10 minute period once |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2004-09-16
- Last updated
- 2023-11-18
Locations
349 sites across 17 countries: United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Italy, Netherlands, New Zealand, Poland, Portugal, Spain, Sweden, Switzerland
Source: ClinicalTrials.gov record NCT00091637. Inclusion in this directory is not an endorsement.